nature.com· Nature Medicine·· 15 hours agoScore67
Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial
In brief
The 5-year analysis of the phase 3 RELATIVITY-047 trial showed statistically significant differences in progression-free survival, overall survival, and melanoma-specific survival between relatlimab plus nivolumab and nivolumab alone in advanced melanoma.
Source: nature.com · nature.com